◆英語タイトル:Alembic Pharmaceuticals Ltd (APLLTD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH51841FSA
◆発行会社(調査会社):
GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. APL also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological and herbal nutraceuticals. APL provides generic formulations such as anti-allergic, antimicrobials, anthelmintic, antiulcerants, nutritional and vitamin preparations, and others speciality products. The company has its research centres and manufacturing facilities in Vadodara, Gujarat and Baddi. APL is headquartered in Vadodara, Gujarat, India.
Alembic Pharmaceuticals Ltd Key Recent Developments
Feb 08,2021: USFDA inspection at Alembic Pharmaceuticals new injectable facility (F-3) at Karkhadi
Jan 19,2021: L2 : Business News | Incuspaze Launches Largest Coworking Space in Vadodara in Association with …
Jul 27,2020: Alembic Pharma gets board approval to raise up to Rs 1,000 crore via QIP
Jun 19,2020: Alembic Pharmaceuticals receives Establishment Inspection Report (EIR) for its general oral solid formulation facility (F-1) at Panelav
May 06,2020: Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals received establishment inspection report (EIR) for its formulation facility at Karkhadi
This comprehensive SWOT profile of Alembic Pharmaceuticals Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Alembic Pharmaceuticals Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 – About the Company
Alembic Pharmaceuticals Ltd – Key Information
Alembic Pharmaceuticals Ltd – Overview
Alembic Pharmaceuticals Ltd – Key Employees
Alembic Pharmaceuticals Ltd – Key Employee Biographies
Alembic Pharmaceuticals Ltd – Key Operational Heads
Alembic Pharmaceuticals Ltd – Major Products and Services
Alembic Pharmaceuticals Ltd – History
Alembic Pharmaceuticals Ltd – Company Statement
Alembic Pharmaceuticals Ltd – Locations And Subsidiaries
Alembic Pharmaceuticals Ltd
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Alembic Pharmaceuticals Ltd – Business Description
Alembic Pharmaceuticals Ltd – Corporate Strategy
Alembic Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Alembic Pharmaceuticals Ltd – Strengths
Alembic Pharmaceuticals Ltd – Weaknesses
Alembic Pharmaceuticals Ltd – Opportunities
Alembic Pharmaceuticals Ltd – Threats
Alembic Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Performance Charts
Alembic Pharmaceuticals Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Appendix
Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Note*: Some sections may be missing if data is unavailable for the company
List of Tables
Alembic Pharmaceuticals Ltd, Key Information
Alembic Pharmaceuticals Ltd, Key Ratios
Alembic Pharmaceuticals Ltd, Share Data
Alembic Pharmaceuticals Ltd, Major Products and Services
Alembic Pharmaceuticals Ltd, History
Alembic Pharmaceuticals Ltd, Key Employees
Alembic Pharmaceuticals Ltd, Key Employee Biographies
Alembic Pharmaceuticals Ltd, Key Operational Heads
Alembic Pharmaceuticals Ltd, Other Locations
Alembic Pharmaceuticals Ltd, Subsidiaries
Alembic Pharmaceuticals Ltd, Key Competitors
Alembic Pharmaceuticals Ltd, SWOT Analysis
Alembic Pharmaceuticals Ltd, Ratios based on current share price
Alembic Pharmaceuticals Ltd, Annual Ratios
Alembic Pharmaceuticals Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios